



# Market Announcement

11 May 2018

---

## Bard1 Life Sciences Limited – Suspension from Official Quotation

### Description

The securities of Bard1 Life Sciences Limited (the 'Company') will be suspended from quotation immediately under Listing Rule 17.2, at the request of the Company, pending the release of an announcement regarding a development contract.

---

<b>Security Code:</b>	BD1
-----------------------	-----

---

### Issued by

**Dale Allen**

Senior Adviser, Listings Compliance (Perth)

14 May 2018

The Manager  
Australian Securities Exchange  
152-158 St Georges Terrace  
PERTH WA 6000

TradingHaltsPerth@asx.com.au  
Sandra.Wutete@asx.com.au  
Via email

## REQUEST FOR VOLUNTARY SUSPENSION

**BARD1 LIFE SCIENCES LIMITED (ASX:BD1) (Company)** requests a voluntary suspension of its securities from ASX effective immediately. The voluntary suspension is requested pending an announcement in relation to an assay development contract.

In accordance with ASX Listing Rule 17.2, the Company provides the following information regarding this request:

1. A halt in the trading of the Company's securities was granted on Thursday the 10<sup>th</sup> of May 2018 pending an announcement by the Company.
2. The Company requests that the voluntary suspension remain in place until an announcement can be made by the Company confirming finalisation of the development contract and the accompanying ASX announcement. Directors expect to be in a position to request the lifting of the voluntary suspension no later than Friday, 18<sup>th</sup> May 2018.
3. The Company is not aware of any reason why the voluntary suspension should not be granted; and
4. The Company is not aware of any further information necessary to inform the market of the voluntary suspension.

For and on behalf of the Board of BARD1 Life Sciences Limited.



**Peter Gunzburg**  
Chairman